Literature DB >> 8762726

Wasting in the acquired immune deficiency syndrome is associated with multiple defects in the serum insulin-like growth factor system.

R A Frost1, J Fuhrer, R Steigbigel, P Mariuz, C H Lang, M C Gelato.   

Abstract

OBJECTIVE: The aim of this investigation was to characterize the GH-IGF axis of patients with AIDS associated wasting. A special emphasis was placed on determining whether IGF binding proteins (IGFBPs) of patients who have lost more than 10% of their ideal body mass are structurally different from the IGFBPs of patients with no weight loss. DESIGN AND PATIENTS: A cross-sectional study of 11 AIDS patients was performed to determine whether the IGF system is abnormal in AIDS patients with wasting. Seven additional AIDS patients were followed longitudinally to determine whether AIDS patients experience long-term changes to their IGF system. MEASUREMENTS: Serum levels of GH and IGF-I were measured by radioimmunoassay, IGF-II was measured by radioreceptor assay, and IGFBP-1 was measured by an enzyme linked immunoassay. IGFBP-3 and IGFBP-3 protease activity were measured by ligand blotting and a BP-3 protease assay, respectively. IGFBP-3 ternary complex formation and IGFBP-1 phosphovariants were analysed by non-denaturing PAGE.
RESULTS: AIDS patients who had lost more than 10% of their ideal body mass demonstrated a 55% reduction in serum IGF-I (81 vs 179 micrograms/l) and a 70% reduction in IGF-II (226 vs 776 micrograms/l), compared to healthy HIV negative subjects. IGF-I levels were depressed, in some patients, despite high serum levels of GH. AIDS patients who had lost more than 10% of their ideal body mass had low levels of IGFBP-3 and a reduced ability to form the IGFBP-3 ternary complex. The IGFBP-3 ternary complex could be restored only upon addition of pure IGFBP-3 and acid labile subunit to serum. Serum IGFBP-1 was increased more than threefold compared to control subjects (90 vs 24 micrograms/l). IGFBP-1 was present as a free phosphoprotein in AIDS patients with low levels of IGF-I and in a bound form when serum IGF-I levels were normal. Changes in the GH-IGF axis were sustained for up to 25 months in AIDS patients with wasting.
CONCLUSIONS: AIDS wasting is associated with a GH resistant state that results in low levels of serum IGF-I, IGF-II and IGFBP-3, elevated levels of phosphorylated IGFBP-1, and a reduced ability to form the IGFBP-3 ternary complex.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8762726     DOI: 10.1046/j.1365-2265.1996.705526.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  22 in total

1.  Metabolic Complications of HIV and AIDS.

Authors:  Alison Strawford; Marc K. Hellerstein
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

2.  Activity of GH/IGF-I axis in trauma and septic patients during artificial nutrition: different behavior patterns?

Authors:  G Pittoni; G Gallioi; M Zanello; L Gianotti; M F Boghen; S Colombo; F Broglio; C Santoro; G Davià; M G Papini; S Destefanis; F Minuto; C Miola; E Ghigo
Journal:  J Endocrinol Invest       Date:  2002-03       Impact factor: 4.256

3.  Responsiveness of muscle protein synthesis to growth hormone administration in HIV-infected individuals declines with severity of disease.

Authors:  M A McNurlan; P J Garlick; R T Steigbigel; K A DeCristofaro; R A Frost; C H Lang; R W Johnson; A M Santasier; C J Cabahug; J Fuhrer; M C Gelato
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

4.  Pharmacokinetics of enfuvirtide in patients treated in typical routine clinical settings.

Authors:  Hartmut Stocker; Charlotte Kloft; Nele Plock; Antje Breske; Guido Kruse; Christian Herzmann; Hubert Schulbin; Peter Kreckel; Christoph Weber; Frank Goebel; Joerg Roeling; Schlomo Staszewski; Andreas Plettenberg; Christiane Moecklinghoff; Keikawus Arastéh; Michael Kurowski
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

5.  Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.

Authors:  Kristine M Erlandson; Suzanne P Fiorillo; Sandra Wagner Cardoso; Cynthia Riviere; Jorge Sanchez; James Hakim; Nagalingeswaran Kumarasamy; Sharlaa Badal-Faesen; Umesh Lalloo; Johnstone Kumwenda; Thomas B Campbell; Todd T Brown
Journal:  AIDS Res Hum Retroviruses       Date:  2017-05-16       Impact factor: 2.205

Review 6.  Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.

Authors:  Shobhit Jain; Ninad Desai; Amrit Bhangoo
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

7.  Low IGF-I levels are often uncoupled with elevated GH levels in catabolic conditions.

Authors:  L Gianotti; F Broglio; G Aimaretti; E Arvat; S Colombo; M Di Summa; G Gallioli; G Pittoni; E Sardo; M Stella; M Zanello; C Miola; E Ghigo
Journal:  J Endocrinol Invest       Date:  1998-02       Impact factor: 4.256

8.  HIV gp120 inhibits the somatotropic axis: a possible GH-releasing hormone receptor mechanism for the pathogenesis of AIDS wasting.

Authors:  S E Mulroney; K J McDonnell; C B Pert; M R Ruff; Z Resch; W K Samson; M D Lumpkin
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

9.  GH/GHRH axis in HIV lipodystrophy.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 10.  Biomedical consequences of alcohol use disorders in the HIV-infected host.

Authors:  Patricia E Molina; Gregory J Bagby; Steve Nelson
Journal:  Curr HIV Res       Date:  2014       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.